Treatment with CT1390B for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational therapy (CT1390B) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the therapy is safe and helps patients with a specific marker called CLL-1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have acute myeloid leukemia (AML) that has returned or has not responded to standard treatment.
- Your leukemia cells must test positive for a marker called CLL-1.
- You have at least 5% leukemia cells (blasts) in your bone marrow.
- You are generally well enough that you can take care of most daily tasks (a score of 0-2 on the ECOG scale).
- Your doctor expects you to live for more than 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental CAR-T cell therapy for acute myeloid leukemia (AML) that has returned or not responded to standard treatments. It uses a special marker on leukemia cells (CLL-1) to target and kill them.
This early-stage study tests an experimental drug called CT0991 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a protein called CD38 on leukemia cells, and the goal is to see if it is safe and helpful.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.